Three drugmakers — Eli Lilly, Novo Nordisk and Sanofi — will testify at the House Energy and Commerce committee hearing on insulin prices April 10, according to The Hill.
The hearing will be the panel's second in two weeks examining the rising cost of insulin in the U.S.
Rep. Diana DeGette, D-Colo, chairman of the committee, told The Hill that the panel also will hear from three of the largest pharmacy benefit managers about their role in driving insulin costs up.
Eli Lilly, Novo Nordisk and Sanofi control 99 percent of the world's insulin. Lawmakers are asking them to explain their pricing.
Before the hearing, Express Scripts, a PBM that merged with health insurer Cigna in 2018, launched an insurance plan that caps insulin costs for patients at $25 a month.